New strategy of global drug R & D changes R & D outsourcing mode

However, now many companies realize that their early pipeline has become increasingly weak Therefore, early drug discovery research has recently become a key point for these companies to operate However, their research strategy in this field has changed significantly New strategy of drug research and development New R & D strategies in the global pharmaceutical industry are evolving Small molecule virtual drug screening model has always been the focus of small biotechnology companies, but now many large pharmaceutical companies also use the same model to screen drugs At the same time, all pharmaceutical companies have realized that early drug discovery is not only to confirm whether a drug works on a target, but also to verify the interaction between the identified treatment target and the compound, and better understand the related problems of disease biology and pathology Therefore, biologically directed drug discovery has become a new trend in the pharmaceutical industry Major pharmaceutical and Biopharmaceutical Enterprises should pay more attention to the progress of disease biology than ever before, so as to find more accurate treatment targets, so as to truly improve the power of drug research and development The original tasks of early drug discovery are mainly the discovery and optimization of leading compounds, the research and optimization of pharmacological properties, while the drug discovery dominated by disease biology now also includes the discovery and verification of biomarkers, as well as the proof of treatment concept in vitro At present, this integrated, cross functional discovery research method has been widely implemented Change R & D outsourcing mode With the change of drug discovery research strategy and practice, major pharmaceutical companies have been changing their outsourcing strategy, from emphasizing risk sharing mode to technical cooperation Finding new therapeutic targets and thoroughly verifying them have become new priorities in drug research and development, so integrated drug discovery outsourcing model has become a general trend For this reason, pharmaceutical companies are more actively involved in the research findings of academia than ever before Almost all major pharmaceutical and biopharmaceutical companies around the world have established close partnerships with a number of academic research institutions in recent years In addition, they are increasingly integrating human genetics research into their discovery and development plans Genomics and proteomics have been widely used in drug development, such as along with the development of diagnostic products and patient stratification The new outsourcing strategy is also creating more extensive cooperation, and the scope of partners is also expanding The original partners are mainly peers, but now also include biotechnology companies and professional outsourcing service providers specializing in technology, and some scholars involved in the identification and confirmation of new drug treatment targets In fact, academia has become the third key factor affecting the research and development of many companies They not only conduct pure theoretical research on disease biology, but also find new biomarkers and their applications in the research New focus on discovery of biological drugs Biological drugs, especially new antibodies, have become as important as traditional small molecule drugs This is why major pharmaceutical companies attach great importance to biopharmaceutical development Many enterprises have created two independent drug R & D systems, small molecule and biological agents Methodologically, the operation of biopharmaceutical discovery is similar to that of small molecules However, antibody has a high demand for the compound library of protein and peptide Similarly, antibody fragments are small in scale, and natural antibodies are also used in the development and research of biological drugs However, in this regard, the most advanced technology is developed by professional biotechnology companies To a large extent, large pharmaceutical companies now rely on the new technology of these professional biotechnology companies to fill their pipeline Emerging countries play an increasingly important role Up to now, the most valuable part of drug discovery research is to build compound libraries with different structures Jzmed, a company specializing in pharmaceutical outsourcing market research, released the latest research report "new trend of global drug discovery outsourcing", pointing out that drug research and development initially used leading discovery platform or high-throughput screening platform to screen thousands of compounds However, this type of R & D work is particularly dependent on the construction of small molecular compound libraries, but few pharmaceutical companies are willing to participate in the construction of libraries, because most drug discovery is outsourced, especially to low-cost emerging countries In recent years, emerging countries, especially China and India, have become the main places for global pharmaceutical companies to find small molecular compounds with diverse structural characteristics On the other hand, some service companies in emerging countries are now able to provide comprehensive drug R & D services As a result, multinational pharmaceutical companies have expanded their outsourcing of discovery research and strengthened their relationships with local partners in these countries Future growth potential According to the research, in the past few years, the global drug R & D outsourcing market has been growing at an average CAGR of about 10.5% Its current market size is estimated at US $13 billion, accounting for nearly 10% of current global drug R & D expenditure The market of small molecule drug discovery outsourcing services accounts for 87% of the global outsourcing services, reaching about US $11.25 billion Between 2009 and 2012, its annual compound growth rate is about 11% At present, the market of biomedical R & D outsourcing is estimated to be only about US $1.75 billion, accounting for 13% of the total outsourcing services However, its annual compound growth rate is about 37% between 2009 and 2012 At present, the average outsourcing penetration rate of small molecule drug discovery research of major companies is estimated to be 40% However, the current average outsourcing penetration rate of biopharmaceutical discovery research is only about 15% The overall average penetration rate of drug discovery research outsourcing is about 30% All pharmaceutical companies have a strong desire to improve the efficiency and productivity of R & D, and the global R & D outsourcing market is expected to show a growth trend in the foreseeable future According to the forecast, the global drug R & D outsourcing market will probably grow at an average compound annual growth rate of about 11.5% from 2013 to 2018, and its market size may reach nearly 25 billion US dollars in 2018 At that time, the overall average penetration rate of the whole industry found in the drug outsourcing research will reach nearly 49% In other words, nearly half of the global drug discovery research will be completed by a third party in 2018 By 2018, in the global market, the outsourcing of small molecule drug discovery will probably account for 3 / 4 of the total, reaching nearly 19 billion US dollars, and the outsourcing of biomedical research and development will probably account for about 1 / 4, and will also exceed 6 billion US dollars.